Liege, Belgium, 24 September 2021 – 7:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces topline results of the Coronesta Phase II study, which aimed to assess the safety and efficacy of estetrol (E4) for the treatment of patients who were hospitalized with moderate COVID-19. E4 is a native occurring estrogen produced by the human fetus during pregnancy.
LIEGE (Belgium – 7:30 AM CEST) and MONTREAL (Canada – 7:00 AM EST), September 15, 2021 – Mithra and Searchlight Pharma are pleased to announce that women across Canada looking for the latest advancement in combined oral contraception (COC) now have access to Nextstellis® , a first-of-its-kind COC that includes the unique natural estrogen estetrol (E4), featuring strong efficacy, safety and tolerability with excellent cycle control. E4 is the first new estrogen in a COC in the Canadian market in more than half a century. E4 is naturally produced in the human body during pregnancy and, in Nextstellis, it is synthesized from plant sources.
21 June 2021, 07:30 CEST – Adelaide, Australia and Liege, Belgium: Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the US commercial launch of Estelle® under the trademark Nextstellis® (3 mg drospirenone and 14.2 mg estetrol (E4) tablets), a new oral contraceptive with a novel estrogen having a unique mechanism of action.
Liege, Belgium, 17 June 2021 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has completed recruitment of the Coronesta Phase II, aiming to assess the protective role of Estetrol in Covid-19 infection. Estetrol is a naturally occurring estrogen produced by the human fetus during pregnancy.
27 May 2021, 07:30 CEST – Adelaide, Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce that the novel oral contraceptive Estelle® – under the trademark Nextstellis® (3 mg drospirenone and 14.2 mg estetrol (E4) tablets) – has been granted marketing exclusivity as a new chemical entity (NCE) from the US Food and Drug Administration (FDA). The exclusivity runs for five years from FDA approval of the New Drug Application for Nextstellis.
Liege, Belgium, 20 May 2021 –18:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, is very pleased to announce that the European Commission has accepted the registration application for the novel combined oral contraceptive Estelle®. This decision follows the adoption of a positive opinion by the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) on 26 March 2021 and is valid for all Member States of the European Union.
15 April 2021, 22:30 CEST, Adelaide, Australia and Liege, Belgium: Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for the novel combined oral contraceptive Estelle® under the trademark Nextstellis® (15 mg Estetrol (E4) / 3 mg drospirenone (DRSP)). Mayne Pharma anticipates the commercial launch of Estelle® by the end of June 2021.
Budapest, Hungary – Liege, Belgium – 26 March 2021 – 13:15 CET – Gedeon Richter Plc. (“Richter”) and Mithra Pharmaceuticals (“Mithra”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for a novel combined oral contraceptive containing 15 mg estetrol (E4) and 3 mg drospirenone (DRSP). Subject to approval by the European Commission, the marketing authorization valid for all European Union Member States is expected to be granted by the end of the second quarter 2021. The product will be marketed in Europe by Richter under the brand name Drovelis®.
“Richter is dedicated to bring to market innovative treatment like Drovelis® that will widen the selection of products within the female contraception solutions”, said Erik Bogsch, Executive Chairman of Gedeon Richter Plc. “We are encouraged by this positive opinion from the CHMP and we shall do our best to make Drovelis® available to physicians and patients in Europe.”
“After Estelle® first approval granted in Canada early this month, we are very pleased with this positive opinion given by the European Medicines Agency”, said Leon Van Rompay, CEO of Mithra. “Being able to offer the result of so many years of work to women is a huge achievement for a biotech such as Mithra. It demonstrates the resilience of our teams which, despite of the turbulences caused by Covid-19, managed to take up the challenge with flying colors. We are pleased to collaborate on this exciting project with our long-standing partner Gedeon Richter as this further strengthens our successful partnership.”
Prof Jean-Michel Foidart, Permanent Secretary of the Royal Academy of Medicine of Belgium, added: “We’ve been working on Estetrol, a native hormone produced by the human body during pregnancy, for more than ten years to develop a new generation contraceptive pill with a clear benefit/risk aiming to improve women’s quality of life. This product promises to be a major breakthrough in a space where there hasn’t been any innovation in decades.”
“This new product has an unique profile, significantly supports reproductive health preservation and conscious family planning. Estetrol combined with drospirenone represents a major innovation breakthrough in reproductive health and sets a new horizon for women around the world,” stated Professor Emeritus György Bártfai, the Chairman of the Egon and Ann Diczfalusy Foundation, founded in 2007 to preserve and forward professor’s spirit and legacy for the next generations.
First E4-based product approved internationally
- Canadian regulatory approval is the first in the world for the novel combined oral contraceptive Estelle®
- Innovative product developed by Mithra containing the unique native estrogen Estetrol (E4) and drospirenone (DRSP)
- Approval supported by two large multinational Phase 3 studies conducted in 3,725 women
- Commercial launch in Canada anticipated mid-summer 2021
LIEGE (Belgium – 7:30AM CET) and MONTREAL (Canada – 7:00AM EST), March 8, 2021 – Mithra and Searchlight Pharma announce today that Health Canada has approved Estelle® under the trademark Nextstellis®, the first and only combined oral contraceptive (COC) product based on the unique native estrogen Estetrol (E4). Once launched, E4 will be the first new estrogen in a COC in the Canadian market in over half a century, and will be the only COC alternative to ethinyl estradiol-based COC pills in Canada.
• Publication of an article on Estelle® endocrine and metabolic parameters in prestigious Contraception Journal
• Article concludes on limited impact of Estelle® compared to Ethinylestradiol-based combined oral contraceptives
• Estelle® filing on going in the U.S., Europe and Canada, with expected marketing authorization in H12021
Liege, Belgium, 9 February 2021– 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the publication of a scientific paper entitled “Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone” in Contraception Journal, one of the most prestigious peer-reviewed journals in the field. A link to this publication can be accessed here.
Rue Saint-Georges 5
Tel. : +32 (0)4 349 28 22
Fax : +32 (0)4 349 28 21
Email : firstname.lastname@example.org